GRAL
T2GRAIL Inc.
OverviewGRAIL Inc. is a commercial-stage biotechnology company focused on multi-cancer early detection. Its flagship Galleri test screens asymptomatic individuals over
GRAIL Inc. is a commercial-stage biotechnology company focused on multi-cancer early detection. Its flagship Galleri test screens asymptomatic individuals over 50, leveraging a proprietary methylation platform for high-accuracy detection. The company also provides development services. In Q2 2026, Galleri screening generated $42.6 million, representing the vast majority of its $44.7 million total revenue, primarily through self-pay and physician orders, with growing employer and international partnerships.
Search Keywords Brand Product
- Galleri test
- NHS-Galleri trial
- PATHFINDER study
- PATHFINDER 2 study
- multi-cancer early detection
- MCED
- cancer screening
- liquid biopsy
- methylation platform
- diagnostic aid for cancer
Search Keywords Event Phrases
- GRAIL earnings
- ASCO Annual Meeting
- FDA AdCom
Search Keywords Policy Regulatory
- FDA approval diagnostics
- Medicare coverage diagnostics
- MCED Act
- PMA application
- FDA advisory committee
- What They Do (Plain English & Analogies)
- GRAIL is a healthcare company that develops and sells a special blood test called Galleri. Think of it like a highly advanced 'smoke detector' for cancer. Instead of waiting for a fire (cancer symptoms) to appear, this test can detect tiny traces of 'smoke' (cancer signals) in your blood very early, even before you feel sick. This is designed for people who don't have any cancer symptoms, typically those over 50, to help find cancer at earlier stages when it's often easier to treat. They also offer tests to help doctors diagnose cancer faster when there's already a suspicion.
- Very Brief History
- GRAIL Inc. was incorporated in 2015. It was acquired by Illumina in 2021 but was later spun off in June 2024 due to antitrust regulatory challenges. The company launched its flagship Galleri test in 2021 and submitted its Premarket Approval (PMA) application to the FDA in early 2026.
- "Street Stereotype"
- GRAIL is generally perceived as a pioneering, high-risk, high-reward company in the multi-cancer early detection (MCED) space. It's seen as a 'high-beta vehicle' for population-level cancer screening, with its Galleri test backed by extensive and rigorous clinical data from interventional studies. However, its path to widespread adoption is viewed as heavily dependent on securing FDA approval and subsequent broad Medicare and commercial reimbursement, which are considered significant regulatory and commercial hurdles. The market also notes its history of being acquired and then spun off from Illumina.
- Subsidiaries On Linked In*
- {"subsidiaries":[]}
- Customer Sectors & Example Clients
- GRAIL's customers are primarily in the healthcare sector, including individual patients (self-pay), healthcare providers (physicians and clinics), employer groups, and health plans. A specific example client mentioned is Priority Health, a nonprofit health plan in Michigan and nearby states, which offers Galleri coverage to its employer groups.
- New Customers / Segments They'Re Targeting
- GRAIL is actively targeting new employer groups and health plans in the U.S. to expand coverage for the Galleri test. Internationally, they are accelerating expansion activities, specifically targeting South Korea through a strategic collaboration with Samsung C&T Corporation, with the potential to expand into additional Asian markets like Japan and Singapore.
- Supply Chain And Sourcing Geographies
- The provided transcript does not offer specific details regarding GRAIL's supply chain or the geographic sourcing of its products or components. It mentions 'sample reprocessing costs,' indicating internal laboratory operations for test processing.
- Sales Geographies And Expansion Plans
- GRAIL currently sells its Galleri test in the United States, primarily through self-pay and expanding employer and payer partnerships. The company is accelerating its international expansion, with plans to commercialize the Galleri test in South Korea through a strategic collaboration with Samsung C&T Corporation. There is also potential to expand into additional Asian markets, including Japan and Singapore.
- How Key Themes May Help/Hurt
- GRAIL is positioned within the 'MedTech Long '26: Diagnostics & Early Detection' theme. This theme can **help** GRAIL through: 1. **Technological Advancements:** Accelerating advancements in genomics, AI, and multiomics directly support GRAIL's proprietary methylation platform and its continuous R&D for test improvements. 2. **Growing Demand:** The increasing global prevalence of cancer and an aging population create a sustained and growing demand for advanced early detection solutions like Galleri. 3. **Favorable Regulatory Environment:** Legislative actions like the MCED Act, which establishes Medicare coverage pathways for FDA-approved MCED tests, are critical for unlocking a massive market for GRAIL. Conversely, the theme's challenges could **hurt** GRAIL: 1. **Reimbursement Pressures:** Persistent reimbursement pressures and evolving payer policies, including potential ASP declines or delayed coverage, could significantly impact Galleri's profitability and market uptake. 2. **Regulatory Hurdles:** Significant regulatory hurdles, lengthy approval processes, and the requirement for extensive evidence generation, particularly for novel MCED tests like Galleri, can impede timely rollout and broad adoption. 3. **Intensifying Competition:** Competition from both established players and new entrants in the diagnostics and early detection space may lead to pricing pressures and increased commercialization costs.
3 Main Long-Term Bull Details
- Unparalleled Clinical Validation and Differentiation: GRAIL's Galleri test is backed by extensive clinical validation from large-scale interventional studies (PATHFINDER, PATHFINDER 2, NHS-Galleri trial) in the intended use screening population, demonstrating strong performance, safety, and clinical utility. This robust evidence base, including a low false positive rate and high accuracy in predicting cancer signal origin, significantly differentiates Galleri from competitors relying on less rigorous data. 2. Proprietary and Technologically Superior Platform: GRAIL's proprietary methylation platform is highlighted as the largest of its kind, uniquely capable of high-accuracy detection and precise localization. The company has published research supporting the superiority of its methylation technology over other genomic approaches, positioning it as a leader in the field with a strong scientific foundation. 3. Significant Market Opportunity with Clear Regulatory Pathway: The anticipated FDA approval of Galleri, expected in the first part of 2027, is a critical catalyst. Coupled with the MCED Act establishing Medicare coverage pathways for FDA-approved MCED tests, this opens up a massive population-level screening market. Growing physician adoption, expanding employer partnerships, and strategic international collaborations (e.g., with Samsung) further underscore the substantial long-term growth potential.
3 Main Long-Term Bear Details
- Regulatory and Reimbursement Uncertainty: While FDA approval is anticipated, the ongoing iterative review process, the upcoming advisory committee meeting, and the subsequent timeline for Medicare and commercial reimbursement decisions represent significant hurdles. Delays or unfavorable coverage policies could impede broad market access and impact profitability. 2. Intense Competition and Market Confusion: The market is experiencing the introduction of other MCED products based on observational case-control data, which GRAIL describes as 'experimental.' This creates 'customer confusion' among physicians and could lead to pricing pressures or slower adoption for Galleri, particularly before FDA approval clearly differentiates it. 3. High Operating Costs and Cash Burn: GRAIL reported a net loss of $110.2 million and an adjusted EBITDA loss of $90.3 million in Q2 2026, indicating substantial ongoing investments in R&D, clinical trials, and commercial expansion. While the company has a strong cash position, sustained high operating costs could pose a long-term challenge without significant revenue growth and improved profitability.
- Competitors And Differentiation
- GRAIL's competitors include other companies developing or launching multi-cancer early detection (MCED) tests. While the transcript does not name specific competitors, it differentiates Galleri from 'experimental MCED tests' that are based only on observational case-control data and lack robust interventional study validation in the intended use screening population. GRAIL's key differentiators are: 1. **Extensive Clinical Validation:** Galleri has undergone extensive clinical validation through large-scale interventional studies (PATHFINDER, PATHFINDER 2, NHS-Galleri trial) in asymptomatic screening populations, demonstrating strong performance and safety. 2. **Superior Technology:** The company utilizes a proprietary methylation platform, which it states is the largest of its kind and uniquely capable of high-accuracy detection and precise localization, supported by published head-to-head genomic feature comparison studies. 3. **Low False Positive Rate:** Galleri boasts a false positive rate of less than 0.5%, resulting in significantly fewer false positives (3x to 6x) compared to other MCED tests in development. 4. **Cancer Signal Origin Prediction:** Galleri demonstrates high accuracy in predicting the cancer signal of origin, which is crucial for efficient and patient-centered diagnostic evaluations. GRAIL aims to be the 'gold standard' MCED, especially upon anticipated FDA approval, creating a clear distinction from other tests.
- Recent Performance & What The Market'S Focused On
- In the second quarter of 2026, GRAIL reported strong financial results with total revenue of $44.7 million, a 26% increase year-over-year. Screening revenue, primarily from the Galleri test, grew 24% to $42.6 million, with test volumes increasing 35% year-over-year to over 61,000 tests. For the first half of 2026, Galleri test revenue grew 30% to over $80 million, and volumes increased 42% to over 117,000 tests. The company's net loss for the quarter was $110.2 million, and adjusted EBITDA loss was $90.3 million. GRAIL ended the quarter with a cash position of $861.6 million, including a $110 million strategic investment from Samsung. The market is primarily focused on the anticipated FDA approval of the Galleri test, expected in the first part of 2027, with an advisory committee meeting likely in the fall of 2026. Other key areas of market focus include securing broad Medicare and commercial reimbursement post-FDA approval, the impact of competition from other MCED tests, the progress of international expansion (especially with Samsung in Asia), the publication of the NHS-Galleri and PATHFINDER 2 study results, and ongoing R&D for Galleri improvements and cost reductions.
- Revenue Segments And Estimated Mix
- Screening revenue — Mix: ~95.3%; Source: Q2 2026 transcript; Trend: Up 24% year-over-year
- Development services revenue — Mix: ~4.5%; Source: Q2 2026 transcript; Trend: n/m
- Product Brands
- Galleri
Bull / Bear DetailsGRAIL remains a leader in multi-cancer early detection, driven by its clinically validated Galleri test, robust commercial growth, and strategic international e
Thesis
GRAIL remains a leader in multi-cancer early detection, driven by its clinically validated Galleri test, robust commercial growth, and strategic international expansion. The anticipated FDA approval in early 2027, following an expected Fall 2026 advisory committee, is a critical catalyst to solidify its 'gold standard' position and unlock broader payer and employer adoption, despite ongoing regulatory complexities and competitive pressures. (Updated: 2026-08-10)
Bull case
Galleri boasts unparalleled clinical validation from large-scale interventional studies like PATHFINDER 2 and NHS-Galleri, demonstrating a 4x-6.5x increase in cancer detection and a false positive rate below 0.5%. This robust evidence, including detection of more early-stage cancers than standard of care, significantly differentiates Galleri from competitors relying solely on observational data.
GRAIL is exhibiting strong commercial momentum, with Q2 2026 Galleri test volume up 35% year-over-year and revenue up 24%. Expanding partnerships, including a new collaboration with Priority Health for employer groups and a $110 million strategic investment from Samsung for Asian market expansion, underscore growing market acceptance and future growth avenues.
The anticipated FDA approval of Galleri in early 2027, following an expected advisory committee in Fall 2026, is a pivotal catalyst. This regulatory milestone is expected to create a market bifurcation, establishing Galleri as the gold standard MCED and unlocking serious engagement from payers and employers, driving significant market access and adoption.
Bear case
Despite strong clinical data, the NHS-Galleri trial's primary endpoint of combined Stage III and IV cancer reduction was not met, which could introduce some uncertainty, even if other results were positive. The ongoing FDA advisory committee process and subsequent CMS coverage decisions represent significant regulatory hurdles and potential delays in broad reimbursement.
Intensifying competition from other 'experimental' MCED tests, which often rely on less robust observational data and exhibit higher false positive rates (3x-5x more than Galleri), is causing customer confusion. This competitive landscape could lead to continued pricing pressures, as evidenced by Galleri's Q2 2026 ASP decrease, and increased commercialization costs.
Scaling commercialization globally presents execution risks. While the Samsung partnership is a positive step for Asian markets, the international expansion is in early stages. Additionally, organizational upheaval within the NHS in the U.K. is causing a hiatus in decision-making regarding future collaborations, potentially delaying broader adoption in key markets.
Bull / Bear Case
- Bear Case
- Despite strong clinical data, the NHS-Galleri trial's primary endpoint of combined Stage III and IV cancer reduction was not met, which could introduce some uncertainty. The ongoing FDA advisory committee process and subsequent CMS coverage decisions represent significant regulatory hurdles and potential delays in broad reimbursement, impacting market access. Intensifying competition from other 'experimental' MCED tests, which often rely on less robust observational data and exhibit higher false positive rates (3x-5x more than Galleri), is causing customer confusion and could lead to continued pricing pressures, as evidenced by Galleri's Q2 2026 ASP decrease. Scaling commercialization globally presents execution risks, with international expansion in early stages and organizational upheaval within the NHS in the U.K. potentially delaying broader adoption in key markets. The company also reported a significant net loss of $110.2 million and an adjusted EBITDA loss of $90.3 million in Q2 2026, indicating substantial cash burn.
- Bull Case
- GRAIL's Galleri test boasts unparalleled clinical validation from large-scale interventional studies like PATHFINDER 2 and NHS-Galleri, demonstrating a 4x-6.5x increase in cancer detection and a low false positive rate below 0.5%. This robust evidence, including detection of more early-stage cancers than standard of care, significantly differentiates Galleri from competitors relying solely on observational data. The company is exhibiting strong commercial momentum, with Q2 2026 Galleri test volume up 35% year-over-year and revenue up 24%. Expanding partnerships, including a new collaboration with Priority Health for employer groups and a $110 million strategic investment from Samsung for Asian market expansion, underscore growing market acceptance and future growth avenues. The anticipated FDA approval in early 2027, following an expected advisory committee in Fall 2026, is a pivotal catalyst expected to establish Galleri as the 'gold standard' MCED, unlocking broader payer and employer adoption.
- More Compelling & Why
- Bear. Given GRAIL's current Price/Sales (P/S) ratio of approximately 18.8x based on a market cap of ~$3.1 billion and TTM revenue of $165.26 million, the bear case is more compelling. This valuation appears stretched for a company with significant ongoing losses and a negative P/E ratio, especially considering the stock underperformed the SPY post-earnings. The strongest argument for the bear case is the regulatory and reimbursement uncertainty, coupled with intense competition causing market confusion and pricing pressure, which could hinder the path to profitability despite strong clinical data. My view would flip to bullish if GRAIL secures FDA approval, a clear and favorable CMS National Coverage Determination, and demonstrates a sustained acceleration in revenue growth with a clear path to positive adjusted EBITDA, justifying a premium valuation.
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| Initial Medicare coverage decisions for FDA-approved MCED tests under the MCED Act and expanded commercial payer coverage for Galleri | Reimbursement is crucial for market access and profitability. Medicare coverage unlocks a massive market, and commercial coverage expands reach to a broader patient population, directly impacting revenue and adoption. | CMS announcements regarding National Coverage Determinations (NCD) for MCED tests. Specific agreements or announcements from major commercial payers (e.g., UnitedHealth, Aetna, Cigna) providing coverage for Galleri. | Bullish: CMS initiates National Coverage Determination (NCD) process for Galleri post-FDA approval, or major commercial payers announce coverage. Bearish: Delays in CMS NCD process, or lack of significant commercial payer adoption post-FDA approval. | CMS website, private payer websites, GRAIL press releases, company earnings calls, industry news. | Google News alerts for 'MCED Act Medicare coverage,' 'Galleri reimbursement.' CMS website, private payer websites for policy updates. | Milliman & Elevance: Commercial covered lives with MCED/ctDNA benefit. |
| Progress of the strategic collaboration with Samsung C&T Corporation for international commercialization of Galleri | This collaboration represents a significant step in GRAIL's international expansion, unlocking new, large markets in Asia. Successful execution can diversify revenue streams and accelerate global adoption. | Specific announcements regarding commercialization timelines, market entry in South Korea, Japan, or Singapore, and initial sales figures from these regions. | Bullish: Clear timelines for market launch in South Korea are announced, or expansion into Japan and Singapore is confirmed. Positive initial sales data from Asian markets. Bearish: Significant delays in market entry or commercialization activities, or lack of concrete progress/expansion beyond South Korea. | GRAIL press releases, company earnings calls, Samsung C&T Corporation announcements. | Google News alerts for 'GRAIL Samsung South Korea,' 'Galleri Japan launch.' | |
| FDA Premarket Approval (PMA) for the Galleri multi-cancer early detection test | FDA approval is the primary regulatory validation, establishing Galleri as a 'gold standard MCED' and creating a market bifurcation. It is a critical prerequisite for broader commercialization, payer coverage, and physician adoption. | Official FDA announcement of Galleri PMA approval. The timing of approval relative to the anticipated 'first part of 2027'. | Bullish: FDA approval received in Q4 2026 or Q1 2027. Bearish: Approval is significantly delayed beyond Q1 2027 or outright rejected. | FDA website (PMA approvals database), GRAIL press releases, SEC filings (Form 8-K), company earnings calls. | Google News alerts for 'GRAIL FDA approval,' 'Galleri PMA.' Industry publications (GenomeWeb, Fierce Biotech). | |
| FDA Advisory Committee (AdCom) meeting for Galleri PMA application | An AdCom is a critical step for groundbreaking technologies like Galleri. A positive recommendation from the committee would significantly de-risk the FDA approval process, signaling strong scientific and clinical support for the test. | Official announcement from the FDA regarding the specific date, agenda, and panel members for the AdCom, anticipated in Fall 2026. The outcome of the AdCom, particularly the panel's recommendation. | Bullish: FDA officially announces AdCom in Fall 2026 and the AdCom provides a positive recommendation. Bearish: AdCom announcement or scheduling is significantly delayed beyond Fall 2026, or the AdCom provides a negative or inconclusive recommendation. | FDA website (Advisory Committees section), GRAIL press releases, SEC filings (Form 8-K if material), company earnings calls. | Google News alerts for 'GRAIL FDA AdCom,' 'Galleri Advisory Committee.' Reddit forums (r/oncology, r/medtech) for discussions. | |
| Sustained or accelerated year-over-year growth in Galleri test volumes | Test volume is a direct indicator of market adoption, commercial execution, and physician/patient acceptance. Strong growth validates the product's value proposition and underpins future revenue expansion. | Quarterly Galleri test volumes and year-over-year growth rates. Number of new ordering providers added per quarter (e.g., ~1,000 in Q2 2026). | Bullish: Quarterly Galleri test volume growth exceeding 35% year-over-year (Q2 2026 rate) and new ordering providers continue to increase (e.g., >1,000 per quarter). Bearish: Quarterly Galleri test volume growth significantly decelerates below 35% year-over-year, or new ordering providers stagnate/decrease. | GRAIL quarterly earnings reports and calls. | Google Trends: 'Galleri test' search volume. LinkedIn: GRAIL sales job postings (growth/contraction). | Earnest Analytics: Diagnostic device sales data for Galleri. Thinknum/LinkUp: GRAIL sales force expansion (hiring data). |
Key Reported Metrics, Reratings Triggers & ResultsThis metric is critical for assessing GRAIL's operational efficiency and cost management as it scales its testing services. Improved gross profit indicates bett
Upcoming print · 2026-11-11
| Key reported metrics | ||
|---|---|---|
| Metric | Last period | Why it matters |
| Non-GAAP Adjusted Gross Profit | 34% | This metric is critical for assessing GRAIL's operational efficiency and cost management as it scales its testing services. Improved gross profit indicates better leverage from higher volumes and cost reductions, directly impacting the company's path to profitability and financial sustainability. |
| Galleri Screening Revenue | 24% | As the primary revenue driver, Galleri Screening Revenue demonstrates the financial success of GRAIL's core product. Its growth rate reflects both increasing test volumes and pricing dynamics, providing a key indicator of the company's overall financial performance and market penetration. |
| Galleri Test Volume | 35% | This metric directly reflects the market adoption and commercial execution of GRAIL's flagship Galleri test. Sustained growth indicates increasing physician and patient uptake, which is crucial for future revenue expansion and validating the test's market demand. |
Last reported · 2026-08-11
| Key reported metrics | Rerating thresholds | ||||
|---|---|---|---|---|---|
| Metric | Last period | Why it matters | What's needed for rerating | Rerating context | Earnings date |
| Galleri Test Volume | This metric is crucial as it directly reflects market adoption and commercial execution of the Galleri test. Sustained and accelerating growth in test volumes validates market demand, strengthens GRAIL's competitive position, and is a key indicator for future revenue expansion and progress towards profitability, especially ahead of anticipated FDA approval and broader reimbursement. | Galleri Test Volume growth exceeding 40% year-over-year for the upcoming report. | This metric is crucial as it directly reflects market adoption and commercial execution of the Galleri test. Sustained and accelerating growth in test volumes validates market demand, strengthens GRAIL's competitive position, and is a key indicator for future revenue expansion and progress towards profitability, especially ahead of anticipated FDA approval and broader reimbursement. | ||
| Non-GAAP Adjusted Gross Profit | Achieving a Non-GAAP Adjusted Gross Profit margin above 50% would signal accelerating operational efficiency and improved unit economics as Galleri test volumes scale. This is crucial for demonstrating a clearer path to profitability and addressing investor concerns about cash burn and financial sustainability, which are key to a positive rerating. | Non-GAAP Adjusted Gross Profit margin needs to hit above 50%. This would represent a significant improvement over the stated current value of 34% and a meaningful increase from the Q2 2026 calculated margin of approximately 48.3%. | Achieving a Non-GAAP Adjusted Gross Profit margin above 50% would signal accelerating operational efficiency and improved unit economics as Galleri test volumes scale. This is crucial for demonstrating a clearer path to profitability and addressing investor concerns about cash burn and financial sustainability, which are key to a positive rerating. | ||
| Galleri Screening Revenue | Hitting this threshold would signal accelerating commercial momentum and market penetration for Galleri, GRAIL's core product. It indicates the company is effectively overcoming competitive pressures and progressing towards its 'gold standard' position, crucial for future FDA approval, broader payer and employer adoption, and ultimately, its path to profitability and a higher valuation. | For the stock to rerate higher, GRAIL's Galleri Screening Revenue needs to demonstrate accelerated year-over-year growth, exceeding the 24% reported in Q2 2026, ideally reaching 30%+ year-over-year. This acceleration would align with the bullish signal of Galleri test volume growth surpassing its Q2 2026 rate of 35% year-over-year. | Hitting this threshold would signal accelerating commercial momentum and market penetration for Galleri, GRAIL's core product. It indicates the company is effectively overcoming competitive pressures and progressing towards its 'gold standard' position, crucial for future FDA approval, broader payer and employer adoption, and ultimately, its path to profitability and a higher valuation. | ||
Key QuestionsWill the FDA Advisory Committee meeting for Galleri in the fall provide a positive recommendation, and will the FDA's timeline for approval remain on track for
Will the FDA Advisory Committee meeting for Galleri in the fall provide a positive recommendation, and will the FDA's timeline for approval remain on track for early 2027?
- Question 2
Can GRAIL's expanded sales force and robust clinical data effectively differentiate Galleri and accelerate physician adoption and test volume growth, particularly against competing 'experimental MCEDs' causing market confusion?
- Question 3
To what extent will the anticipated FDA approval catalyze broader commercial payer and employer coverage for Galleri, driving significant increases in covered lives and reimbursement?
Earnings Transcript Summary
· 2026Q2 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 3 Things Management Is Most Focused On1. Securing FDA approval and broad reimbursement for Galleri: Management is focused on driving to FDA approval, anticipating an advisory committee in the fall, and securing subsequent Medicare and commercial reimbursement for Galleri, viewing FDA approval as a 'landmark event' that will create a market bifurcation. 2. Expanding Galleri access and international commercialization: This includes expanding access through new and existing partnerships in the U.S. (e.g., Priority Health collaboration) and accelerating international expansion, highlighted by the $110 million Samsung financing and strategic collaboration for South Korea and potential other Asian markets. 3. Leveraging strong clinical evidence to drive market development: Management is focused on educating clinicians about the positive performance, safety, and clinical utility results from the PATHFINDER 2 and NHS-Galleri trials, presented at ASCO, and utilizing the expanded field sales and medical teams to reinforce Galleri's extensive clinical validation. | Call Takeaway & ToneThe call conveyed a confident and positive tone, despite ongoing regulatory processes and market competition. Management highlighted strong Q2 2026 growth in Galleri test volume and revenue, emphasizing the unparalleled clinical evidence from PATHFINDER 2 and NHS-Galleri trials. The key takeaway is GRAIL's strong position in the multi-cancer early detection (MCED) market, driven by robust clinical validation, strategic international expansion (Samsung), and an anticipated FDA approval in early 2027, which they believe will solidify Galleri's 'gold standard' status and clarify market confusion caused by less-validated competitors. They are actively preparing for an FDA advisory committee meeting in the fall. | Prior Quarter'S Y/Y Growth By SegmentIn Q1 2026, total revenue grew 28% year-over-year. Screening revenue increased 37% year-over-year. Galleri test volume grew 50% year-over-year. Development services revenue was $1 million (year-over-year growth not specified). | 3 Things Analysts Most Pressed On (And Mgmt Responses)1. FDA Advisory Committee (AdCom) focus and timing: Analysts repeatedly asked about the FDA's focus for the anticipated AdCom, potential delays, and the specific communication leading to the expectation of an AdCom. Management responded that they are preparing internally but do not know the specific nature of the questions or timing yet, beyond anticipating it in the fall. They reiterated their long-held expectation for an AdCom for a groundbreaking technology like Galleri and that their current anticipation for potential approval in early 2027 remains unchanged, clarifying the AdCom would be solely about Galleri's data. 2. Impact of competition on pricing and market confusion: Analysts inquired about the impact of other MCED products on GRAIL's pricing (noting a decrease in ASP) and the general market environment. Management attributed the ASP decrease to the expansion of digital health volume and planned lower employer pricing. They acknowledged 'active competition' causing 'customer confusion' due to other 'experimental MCEDs' lacking interventional study data and having higher false positive rates, believing FDA approval for Galleri will create a market 'bifurcation,' establishing Galleri as the 'gold standard MCED.' 3. Impact of FDA approval on the business before Medicare coverage: Analysts asked about the implications of FDA approval on payer adoption, employer interest, and volumes in the interim period before a potential Medicare decision. Management stated that FDA approval is the 'gate that a lot of payers have been waiting for' to engage in serious conversations and that many employers are also waiting for it. They believe it will give providers confidence in Galleri as the 'gold standard MCED,' boosting sales efforts and overall market development. | Revenue SegmentsTotal revenue was $44.7 million, up 26% year-over-year. Screening revenue was $42.6 million, up 24% year-over-year. Development services revenue was $2 million (year-over-year growth not specified). Galleri test volume increased 35% year-over-year to over 61,000 tests. |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|
| About Expanding Eligible MarketGRAIL is expanding access through new and existing partnerships and accelerating international expansion, including a strategic collaboration with Samsung C&T Corporation to commercialize the Galleri test in South Korea and potentially other Asian markets like Japan and Singapore. In the U.S., Galleri test volume increased 35% year-over-year to over 61,000 tests in Q2 2026, with revenue up 24% to $42.6 million. For the first half of 2026, volume grew 42% to over 117,000 tests, and revenue grew 30% to over $80 million. The company announced a collaboration with Priority Health to offer Galleri to its employer groups, expanding an existing partnership. Self-pay remains the majority of Galleri's volume at about 70%, and GRAIL added approximately 1,000 new ordering providers in Q2. Electronic order integrations with Quest and Athena are also contributing to new prescribers and increased prescribing depth. Strong growth is also seen in digital health and employer partnerships. | About CompetitionGalleri's performance is highly differentiated with a false positive rate of less than 0.5%, which is 3x to 6x fewer than other MCED tests in development. GRAIL's proprietary methylation platform is uniquely capable of high accuracy detection and precise localization, and the company has published the largest head-to-head genomic feature comparison study, showing methylation's superiority. Other MCED products are based only on observational case-control data, lacking interventional study validation in a screening population, making their benefits and harms unknown. These 'experimental' MCED tests have 3x to 5x higher false positive rates, detect fewer cancer types, and some lack cancer signal origin prediction. GRAIL anticipates FDA approval will create a market bifurcation, establishing Galleri as a well-validated, potentially FDA-approved MCED, distinct from other experimental tests with unknown risk-benefit profiles. Competition has caused customer confusion due to these experimental MCEDs' higher false positive rates and unclear performance characteristics. | About The Broader IndustryStandard of care screening currently finds only about 14% of cancers in the U.S. and 6% in the U.K., which Galleri aims to increase to 50% or more. Multi-cancer early detection represents a potential paradigm shift in cancer screening, offering the promise of finding cancer early enough for curative treatment options. The industry demands robust evidence from interventional clinical studies in the intended use population to demonstrate true test performance, including benefits and harms. Changes in the NHS organizational structure and governance in the U.K. are causing decision-making hiatus and uncertainty regarding future structures for diagnostic aid for cancer conversations. | Where Things Are HeadedGRAIL is focused on driving to FDA approval and subsequent Medicare and commercial reimbursement for Galleri, with an anticipated approval in the first part of 2027. The company expects the FDA to convene an advisory committee (AdCom) for Galleri in the fall of 2026. Following ASCO, expanded field teams are fully equipped to educate clinicians on trial results and continue market development. Future plans include expanding international distributor partnerships, progressing R&D for Galleri improvements and cost reduction, and publishing NHS-Galleri and PATHFINDER 2 studies. FDA approval is seen as a critical 'gate' for serious conversations with payers and employers, and it is expected to establish Galleri as the 'gold standard MCED' for providers. Publications for PATHFINDER-2 and NHS-Galleri are in active review at top-tier journals and are hoped for in the near future. CMS is assumed to undertake a national coverage analysis only upon FDA approval. | Updates On ThemeDiagnostics | Bullish-Leaning Quotes (Short)GRAIL continues to execute across our clinical and commercial priorities. Galleri test performance is highly differentiated with a false positive rate of less than 0.5%. The field is increasingly moving to methylation as the technology of choice, further validating our approach. We sold over 61,000 Galleri tests in the second quarter, a 35% increase in volume year-over-year. Across both studies, adding Galleri to standard of care increased the cancer detection rate by 4x to 6.5x. Galleri detected 366 Stage I and II cancers, many more than the 290 cancers detected at any stage by the entirety of the U.K.'s standard of care screening program in the control arm. This is truly remarkable. We are very confident in the data package that's been submitted. GRAIL is defined by rigorous science and validated by the most extensive evidence base. FDA approval is really the gate that a lot of payers have been waiting for to really dig into Galleri and serious conversations. FDA approval is going to give providers the confidence that Galleri is the gold standard MCED. | Bearish-Leaning Quotes (Short)Although the primary endpoint for the NHS-Galleri trial of a combined reduction of Stage III and IV cancers was not met, we believe the other results of the study demonstrated very strong performance, safety and utility. Other MCED products have been introduced based only on observational case control data and have yet to evaluate the benefits and harms in an actual screening population. MCED tests with high false positive rates may expose patients to significant risks of radiation exposure and invasive diagnostic tests, which carry potential for complications and increased morbidity. Experimental MCED tests are operating at a 3x to 5x higher false positive rate. Active competition that we've seen that has been stepped up... causing some customer confusion in the market. The fundamental changes in the sort of organizational structure and governance for NHS services in the U.K. is causing some hiatus in decision-making. | HiringGRAIL announced a planned expansion of its field sales and medical teams early in 2026, which was substantially complete by the end of the second quarter. New personnel have been onboarded, trained, and are now in the field. This expansion was pulled forward based on positive performance and clinical utility results from the NHS-Galleri and PATHFINDER 2 trials, aiming to have the new salespeople in territory and trained to meet the moment of anticipated FDA approval. |
Upcoming Events
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| GRAL_88e14714 | in the fall | 2026-09-01 | 2026-11-30 | FDA Advisory Committee meeting for GRAIL's Galleri multi-cancer early detection test. | This meeting is a critical step in the FDA approval process for Galleri, providing external expert advice to the FDA and signaling progress towards regulatory validation. | Ticker | 2026-08-05 | earnings_transcript |
| GRAL_1d85fec4 | in the first part of 2027 | 2027-01-01 | 2027-06-30 | FDA approval of the Galleri multi-cancer early detection test following its Premarket Approval (PMA) application. | FDA approval would provide critical regulatory validation, de-risk the technology, and pave the way for broader commercialization, payer coverage, and physician adoption. | Ticker | 2026-08-05 | earnings_transcript |
| GRAL_d22d5a9a | in the near future | 2026-08-10 | 2026-11-10 | Publication of detailed performance, safety, and clinical utility results from the NHS-Galleri and PATHFINDER 2 trials in top-tier journals. | Publication in top-tier journals provides further scientific validation and enhances credibility, supporting physician adoption and payer discussions for Galleri. | Ticker | 2026-08-05 | earnings_transcript |